Travailler chez Siemens HealthineersEspace presseInvestor Relations
  1. Home
  2. Imagerie Médicale
  3. Molecular Imaging
  4. Nuclear Medicine News & Stories
  5. Sequential Quantitative SPECT/CT Following Therapeutic Administration of 177Lu DOTATATE In a Patient with Liver Metastases from Neuroendocrine Tumor

Sequential Quantitative SPECT/CT Following Therapeutic Administration of 177Lu DOTATATE In a Patient with Liver Metastases from Neuroendocrine Tumor

Peter Bartenstein, MD
Data courtesy of Ludwig Maximillians University, Munich, Germany|2018-08-07
Sequential quantitative SPECT/CT at four time points

A 69-year-old male with intestinal carcinoid tumor with multiple liver metastases, confirmed using 68Ga-DOTATOC PET/CT imaging, was referred for radionuclide therapy with 177Lu DOTATATE. Following administration of the first therapeutic dose of 177Lu DOTATATE, the patient underwent SPECT/CT studies performed at 2, 24, 48, and 72 hours after injection to assess tracer concentration across four time points.

xSPECT Quant is not commercially available in some countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

The outcomes by Siemens Healthineers customers described herein are based on results that were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.